Stonebridge Financial Group LLC Grows Stake in Medtronic PLC $MDT

Posted by Brenda Bartman on Aug 4th, 2026

Stonebridge Financial Group LLC raised its holdings in shares of Medtronic PLC (NYSE:MDT – Free Report) by 18.4% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 54,010 shares of the medical technology company’s stock after purchasing an additional 8,397 shares during the period. Stonebridge Financial Group LLC’s holdings in Medtronic were worth $4,225,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in MDT. Anfield Capital Management LLC grew its stake in Medtronic by 410.7% during the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after buying an additional 230 shares during the last quarter. Monetary Solutions Ltd acquired a new stake in Medtronic in the fourth quarter worth about $27,000. Acumen Wealth Advisors LLC acquired a new stake in Medtronic in the fourth quarter worth about $29,000. Imprint Wealth LLC purchased a new stake in shares of Medtronic during the third quarter worth about $31,000. Finally, Basepoint Wealth LLC acquired a new position in shares of Medtronic during the fourth quarter valued at about $32,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Insider Activity at Medtronic

In related news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the transaction, the executive vice president directly owned 37,227 shares of the company’s stock, valued at approximately $2,994,539.88. This represents a 10.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.26% of the company’s stock.

Medtronic Stock Up 1.5%

MDT opened at $86.67 on Tuesday. The company has a market cap of $110.94 billion, a PE ratio of 23.23, a price-to-earnings-growth ratio of 2.29 and a beta of 0.56. Medtronic PLC has a twelve month low of $73.31 and a twelve month high of $106.33. The company has a 50-day moving average price of $81.10 and a 200 day moving average price of $86.93. The company has a quick ratio of 1.62, a current ratio of 2.13 and a debt-to-equity ratio of 0.52.

Medtronic (NYSE:MDT – Get Free Report) last posted its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.01. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The company had revenue of $9.81 billion for the quarter, compared to analysts’ expectations of $9.62 billion. During the same period in the previous year, the firm posted $1.62 EPS. Medtronic’s revenue was up 9.9% compared to the same quarter last year. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Sell-side analysts expect that Medtronic PLC will post 5.94 earnings per share for the current fiscal year.

Medtronic Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, July 17th. Stockholders of record on Friday, June 26th were paid a $0.72 dividend. This is a boost from Medtronic’s previous quarterly dividend of $0.71. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date of this dividend was Friday, June 26th. Medtronic’s dividend payout ratio is presently 77.21%.

Analyst Upgrades and Downgrades

A number of research firms recently commented on MDT. Robert W. Baird lowered their target price on shares of Medtronic from $93.00 to $85.00 and set a “neutral” rating for the company in a research note on Thursday, June 4th. BTIG Research restated a “buy” rating and set a $91.00 price target on shares of Medtronic in a research note on Monday, July 13th. Evercore set a $105.00 price objective on shares of Medtronic in a research note on Monday, July 6th. JPMorgan Chase & Co. dropped their price objective on shares of Medtronic from $100.00 to $86.00 and set a “neutral” rating on the stock in a report on Thursday, June 4th. Finally, Truist Financial lowered their price target on Medtronic from $95.00 to $86.00 and set a “hold” rating for the company in a research report on Thursday, June 4th. Eighteen investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $98.83.

Get Our Latest Stock Analysis on MDT

Medtronic Company Profile

(Free Report)

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).